19, 11161129 (2017). Cold Spring Harb. Sci. 7, 279ra240 (2015). Davids, M. S. et al. Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study. Pharmacol. Phase I study of recombinant human tumor necrosis factor. 6, e1590 (2015). 30 (Suppl. SMAC mimetic Debio 1143 and ablative radiation therapy synergize to enhance antitumor immunity against lung cancer. Soderquist, R. S. et al. de Jong, Y. et al. Biol. Nat. Natl Acad. Nat. https://doi.org/10.1038/s41571-020-0341-y. J. Biol. Cancer Biol. J. Clin. Soria, J. C. et al. Oncotarget 9, 2919329207 (2018). 16, 12561263 (2010). Cell Death Differ. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Proc. Oncol. 66, 76617667 (2006). Cell 126, 177189 (2006). 35, 4748 (2017). 9, 890909 (2019). Article & Strasser, A. 14, 20212034 (2007). 186, 11651170 (1997). Bogenberger, J. M. et al. Chiron, D. et al. Shi, P. et al. Ishizawa, J. et al. Targeting therapies for the p53 protein in cancer treatments. The clinical translation of effective pro-apoptotic agents involves drug discovery studies (addressing the bioavailability, stability, tumour penetration, toxicity profile in non-malignant tissues, drug interactions and off-target effects) as well as an understanding of tumour biology (including heterogeneity and evolution of resistant clones). Hallin, J. et al. Cell Death Dis. Deroose, J. P. et al. Finnberg, N. et al. & El-Deiry, W. S. Overview of cell death signaling pathways. 1 Apoptosis is the normal physiological response to many stimuli, including irreparable DNA damage. 10, 1689 (2019). Ann. 45, 528537 (2000). Chang, Y. S. et al. Konopleva, M. et al. Cell 80, 285291 (1995). I. Biosci. Guicciardi, M. E. & Gores, G. J. Chem. Characterization of peptide aptamers targeting Bfl-1 anti-apoptotic protein. 15, 54575465 (2009). 8, 639645 (2012). Apoptosis is the cell's natural mechanism for programed cell death. Clin. Fakih, M. et al. Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. PLoS One 5, e13026 (2010). Google Scholar. Mol. J. Mol. Soc. Chem. The receptor for the cytotoxic ligand TRAIL. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. 1, 933946 (2017). Chem. https://cancer.sanger.ac.uk/cosmic, gnomAD: Mol. Cancer Cell 33, 890904 (2018). Cell Death Dis. J. 26, 55885594 (2006). A tumor suppressor gene is like the brake pedal on a car. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Structure 26, 153160 (2018). Leukemia 33, 262266 (2019). Immunol. Mol. 5, 662667 (2014). Chem. Cancer 122, 588597 (2016). Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL. Ciuleanu, T. et al. Cell 170, 10621078 (2017). Chem. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer. Cell Biol. 559, 1932 (2009). Cell 177, 10941107 (2019). Sci. Chaudhary, P. M. et al. 10, 6675 (2003). Leverson, J. D. et al. 16, 53865397 (1997). Blood 134, 111122 (2019). Clin. This is a preview of subscription content, access via your institution. Clin. Cancer cell death involves two broadly defined mechanisms: programmed cell death and necrosis. Tan, T. T. et al. Nat. Cancer Chemother. https://www.clinicaltrials.gov, Carneiro, B.A., El-Deiry, W.S. 26, 894901 (2015). Cancer Res. Inhibition of oncogenic Wnt signaling through direct targeting of -catenin. Its development and progression are usually linked to a series of changes in the activity of cell cycle regulators. Pennica, D. et al. 271, 74407444 (1996). Clin. ISSN 1759-4782 (online) Furthermore, flow cytometry results showed that the M protein induces apoptosis in 91 % of CRC cells. Nature 396, 699703 (1998). Res. Fischer, K. et al. Cancer Discov. Ellis, R. E., Yuan, J. Y. Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils. Inuzuka, H. et al. Invest. PubMed Boroughs, L. K. & DeBerardinis, R. J. Metabolic pathways promoting cancer cell survival and growth. Apoptosis Deregulation and the Development of Cancer Multi-Drug Cancer Res. W.S.E-D. is an American Cancer Society Research Professor and the Mencoff Family University Professor at Brown University. 186, e188e191 (2019). Cell 168, 692706 (2017). 77, 30013012 (2017). A new Bcl-2 inhibitor (S55746/BCL201) as monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: preliminary results of the first-in-human trial. Cancer and the cell cycle | Biology (article) | Khan Academy J. Clin. J. Med. 77 (Suppl. 21, 491502 (2014). 4, eaaw2004 (2019). Natl Acad. Clearing the final hurdles to mitochondrial apoptosis: regulation post cytochrome C release. Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. 37 (Suppl. Dev. Cell 57, 6982 (2015). Drug. Fang, D. D. et al. Nat. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Arrillaga, I. et al. Commun. Ozoren, N. & El-Deiry, W. S. Defining characteristics of types I and II apoptotic cells in response to TRAIL. Revised dose ramp-up to mitigate the risk of tumor lysis syndrome when initiating venetoclax in patients with mantle cell lymphoma. Clin. Luhr, M. et al. Curr. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Blood 113, 17231729 (2009). J. Clin. Cell 156, 317331 (2014). Res. 32, 31033110 (2014). Liu, X., Kim, C. N., Yang, J., Jemmerson, R. & Wang, X. Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol. Furthermore, we built a nomogram using these ARGs to forecast the . 9, 25 (2016). Nat. Giampazolias, E. et al. Structure-guided design of a selective BCL-X(L) inhibitor. Rongvaux, A. et al. Cancer Res. Cancer Cell 35, 830849 (2019). The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells. 18, 521528 (2012). Bleicken, S. et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Article A limited number of FDA-approved anticancer agents directly target apoptotic pathways; these small molecules are designed to inhibit anti-apoptotic BCL-2 family members. Clin. Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Rev. Phase I study of recombinant tumor necrosis factor in cancer patients. Morgan-Lappe, S. E. ABBV-621: a best-in-class TRAIL-receptor agonist fusion protein that enhances optimal clustering for the treatment of solid and hematologic tumors [abstract]. Grossmann, T. N. et al. Leverson, J. D. et al. Blombery, P. et al. The TP53 gene is a gene that is mutated in many cancers. The Hox genes and their roles in oncogenesis | Nature Reviews Cancer 4, 362375 (2014). BAK/BAX macropores facilitate mitochondrial herniation and mtDNA efflux during apoptosis. Baumann, C., Ullrich, A. Pathways of apoptosis in lymphocyte development, homeostasis, and disease. 57, 62756288 (2014). Kline, C. L. B. et al. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Sci. A first-in-human phase I study of OPB-111077, a small-molecule STAT3 and oxidative phosphorylation inhibitor, in patients with advanced cancers. Cell Rep. 24, 33933403.e5 (2018). 13), 2391 (2019). Hematol. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. J. Clin. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Plummer, R. et al. Ther. Targeted therapy of the XIAP/proteasome pathway overcomes TRAIL-resistance in carcinoma by switching apoptosis signaling to a Bax/Bak-independent type I mode. USA 115, E886E895 (2018). Blood Adv. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Cancer Res. Scorrano, L. et al. Oncol. Am. Anlotinib is a multitargeted tyrosine kinase inhibitor that inhibits tumor progression by targeting angiogenesis-related growth factor receptors, including VEGFR 1/2/3, FGFR 1/2/3, and other tumor-associated kinases, such as c-Kit and Ret. & Fenton, R. G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Wu, G. S. et al. Cancer 17, 637658 (2017). Eur. Med. Mol. J. Immunother. 68, 34213428 (2008). Cancer Res. Cancer Cell 23, 121128 (2013). & Meier, P. Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation. Yang, W. S. et al. Clin. N. Engl. Noonan, A. M. et al. Clin. Caspase-8 induces cleavage of gasdermin D to elicit pyroptosis during Yersinia infection. Yang, J. et al. Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. 5, 101110 (2011). Tumour Biol. Hata, A. N. et al. As . Zelenetz, A. D. et al. Andreeff, M. et al. 13), 262 (2019). A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI [abstract]. 51, 415423 (2007). 294, 81978217 (2019). Trarbach, T. et al. Cancer Cell 35, 721737 (2019). Clin. How apoptosis is regulated, and what goes wrong in cancer Internet Explorer). Levy, D. S., Kahana, J. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Oncogene 22, 12811293 (2003). CAS Prolonged idasanutlin (RG7388) treatment leads to the generation of p53-mutated cells. 17, 333340 (2017). ISSN 1759-4774 (print). Cancer Res. Apoptosis: A Target for Anticancer Therapy - PMC Sallman, D. A. et al. Contributions of HOX genes to cancer hallmarks: Enrichment pathway Precision targeting of BFL-1/A1 and an ATM co-dependency in human cancer. 8, 292302 (2009). Nat. New Drugs 37, 210222 (2019). 64, 463472 (2009). Park, J. S. et al. Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. 25, 486541 (2018). Zhang, L. et al. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. The antitumour efficacy of several FDA-approved agents targeting cell survival and proliferation pathways in cancer cells is also dependent on their effects on apoptosis signalling pathways. EMBO J. Cancer Res. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Accelerated degradation of caspase-8 protein correlates with TRAIL resistance in a DLD1 human colon cancer cell line. 36, 31263133 (2018). Garner, T. P. et al. Both cell-mediated immunotherapy and immune-checkpoint inhibition induce apoptosis in cancer cells through the extrinsic pathway; the possibility of potentiating this effect using combination regimens (involving targeted therapies, cytotoxic agents or radiotherapy) is currently under investigation. 63, 54625469 (2003). Blandino, G. & Di Agostino, S. New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Cancer Res. PubMed Central Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death. J. Biol. N. Engl. 9, 3513 (2018). Blombery, P. et al.